Avinger Announces Participation in Cowen and Company 38th Annual Health Care Conference
March 05, 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif, March 05, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the...
Avinger Regains Compliance with Nasdaq Listing Requirements
March 02, 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced it has...
OPS Code Established for Peripheral Vascular OCT Imaging in Germany
February 20, 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that the German...
Avinger Announces Closing of $18 Million Underwritten Public Offering
February 16, 2018 13:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the closing of...
Avinger Announces Pricing of $18 Million Underwritten Public Offering
February 14, 2018 08:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the pricing of...
Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Leipzig Interventional Course 2018
February 02, 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that its next...
Avinger Announces Reverse Stock Split
January 30, 2018 16:45 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the...
Avinger Granted Continued Listing Decision From Nasdaq
January 19, 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the...
Avinger Announces Treatment of First Patients Globally With Next Generation Pantheris
January 03, 2018 08:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that Arne Schwindt,...
Avinger Announces 510(k) Filing of Next Generation Pantheris Device
December 21, 2017 08:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced the Company submitted...